Vertex Pharma stock rises to EUR 455.50, P/ E 29.7 amid gains

Published on 10/09/2026 at 19:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Vertex Pharma stock stood EUR 6.60 above its prior close of EUR 448.90 on October 9, 2026. Its 52-week range is USD 402.58 to USD 560.25.

Key points in brief

Vertex Pharma stock rose to EUR 455.50 at Lang & Schwarz on October 9, 2026, up 1.47 percent versus EUR 448.90.
The Nasdaq-listed stock had a USD 402.58 to USD 560.25 52-week range and a P/E ratio of 29.69.
Vertex reported USD 3.33 billion in second-quarter 2026 revenue and USD 1.10 billion in net income.
Third-quarter 2026 results are scheduled for November 2, 2026, after the US market close.

Extreme Nahaufnahme von Pharmakapseln und Tabletten auf glänzender Glasoberfläche — Vertex Pharma US92532F1003 zeigt eine Makroaufnahme von Pharma-Kapseln und Tabletten mit feinen Wassertropfen, Illustration mit AI erstellt.

Vertex Pharma stock rose to EUR 455.50 at Lang & Schwarz on October 9, 2026, up 1.47 percent versus the prior close of EUR 448.90. The move places the German-market quote below the company’s USD 560.25 yearly high while the Nasdaq valuation remains central to the market report.

Price gains as valuation stays high

The Lang & Schwarz quote was EUR 6.60 above the prior close, with a bid of EUR 455.05 and an ask of EUR 455.95 at 7:49 p.m. CEST. On the Nasdaq, Vertex Pharmaceuticals was last at USD 510.02 at 1:53 p.m. ET on October 9, 2026.

The Nasdaq quote sits between a 52-week low of USD 402.58 and a high of USD 560.25. Trading volume was 522,839 shares against an average volume of 1,148,681 shares, giving the session a lighter turnover profile than the recent average.

Revenue and earnings provide scale

Vertex reported USD 3.33 billion in revenue for the second quarter of 2026, up from USD 2.96 billion in the second quarter of 2025. Net income reached USD 1.10 billion in the second quarter of 2026 versus USD 1.03 billion a year earlier, according to Markets Insider on October 7, 2026.

That comparison matters because the current quote carries a trailing P/E ratio of 29.69 and a market capitalization of USD 129.4 billion. The valuation is materially higher than Regeneron Pharmaceuticals at a P/E ratio of 18.51, while Alnylam Pharmaceuticals stood at 39.26.

Comparison with peers

Vertex Pharma: plus 1.47 percent, P/E 29.69, market capitalization USD 129.4 billion
Regeneron Pharmaceuticals (Nasdaq, USD): plus 1.14 percent, P/E 18.51, market capitalization USD 77.1 billion
Alnylam Pharmaceuticals (Nasdaq, USD): plus 3.42 percent, P/E 39.26, market capitalization USD 31.1 billion

Next results date is November 2

Vertex Pharmaceuticals announced on October 7, 2026 that it will report third-quarter 2026 results on November 2, 2026, after the financial markets close. The company scheduled its conference call for 4:30 p.m. ET.

Markets Insider reported on October 7, 2026 that Morgan Stanley assigned Vertex a Buy rating and a USD 665.00 price target. The target is a separate US-dollar reference and is not combined with the EUR 455.50 Lang & Schwarz quote.

Quote remains below yearly high

Vertex Pharma stock was trading at EUR 455.50 at Lang & Schwarz on October 9, 2026 at 7:49 p.m. CEST, plus 1.47 percent versus the Lang & Schwarz prior close of EUR 448.90 on October 8, 2026. The continuously updated real-time quote of Vertex Pharma stock.